Gastric Cancer
Conditions
Brief summary
SUMMARY Rationale: Diagnostic laparoscopy (DL) and response assessment after neoadjuvant chemotherapy with computed tomography (CT) are two diagnostic modalities used to assess metastatic spread in gastric cancer patients. It is still unclear in what proportion of patients clinically relevant metastases or other significant findings (e.g. contra-indications of surgery) are detected that impact on the treatment. Objective: To determine the clinical value of diagnostic laparoscopy and computed tomography response assessment after neoadjuvant chemotherapy in patients with gastric and esophagogastric junction adenocarcinoma. Study design: Multicentre retrospective cohort study. Study population: All Patients with gastric and gastro-oesophageal adenocarcinoma who underwent clinical staging and were discussed at multidisciplinary team meetings (MDT) between January 2016 and December 2018. Intervention (if applicable): Not applicable. Main study parameters/endpoints: The main study parameter is the proportion (%) of patients who do not proceed with treatment as planned after a DL and CT response assessment (i.e. the proportion of patients in which metastasized disease or other contra-indications for surgery is found). Nature and extent of the burden and risks associated with participation, benefit and group relatedness: Since this is an observational study, no burden or risks are associated with participation.
Interventions
DIAGNOSTIC_TESTComputed tomography
Computed tomography to gauge response after preoperative chemotherapy cycles and excluded the development of interval metastases or irresectable disease
DIAGNOSTIC_TESTDiagnostic laparoscopy with peritoneal lavage
Diagnostic laparoscopy lavage to exclude (small-volume) metastases and determine local resectability
Sponsors
Sander van Hootegem
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients with histologically proven gastric and esophagogastric junction adenocarcinoma. * Patients who have had (either) DLS and/or CT response assessment (after chemotherapy). * Discussed at MDT from January 2016 - December 2018 * ≥18 years
Exclusion criteria
* Patients with esophagogastric junction adenocarcinoma with the tumour bulk located in the oesophagus that receive neoadjuvant chemoradiation; * Patients with recurrent/residual disease after earlier treatment of gastric cancer.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in treatment | 1 month (on average) | Proportion of patients in which the diagnostic test led to change in treatment/management |
Countries
Netherlands
Outcome results
None listed